Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 8;3(1):e000151.
doi: 10.1136/bmjresp-2016-000151. eCollection 2016.

Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD

James L Kreindler  1 , Michael L Watkins  2 , Sally Lettis  3 , Ruth Tal-Singer  1 , Nicholas Locantore  1
Affiliations

Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD

James L Kreindler et al. BMJ Open Respir Res. .

Abstract

Introduction: Sputum and blood eosinophil counts have attracted attention as potential biomarkers in chronic obstructive pulmonary disease (COPD). One question regarding the use of blood eosinophils as a biomarker in COPD is whether their levels are affected by the use of inhaled corticosteroids (ICS), which are commonly prescribed for COPD.

Methods: We performed a retrospective analysis of peripheral blood leucocytes from a previously completed clinical trial that examined effects of ICS in steroid-naïve patients with COPD.

Results and conclusion: The data show that the ICS-containing treatment arms (containing fluticasone propionate) had a small effect on peripheral blood eosinophils in steroid-naïve patients with COPD.

Trial registration number: NCT00358358; Post-results.

Keywords: COPD Pharmacology; Eosinophil Biology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Empirical distribution function for SCO104925 patients and the ECLIPSE cohorts.
Figure 2
Figure 2
Peripheral blood eosinophil levels based on a threshold of (A) 150 cells/μL, patients not randomised to inhaled corticosteroids (ICS)-containing treatment (n=59), (B) 150 cells/μL, patients randomised to ICS-containing treatment (n=53), (C) 300 cells/μL, patients not randomised to ICS-containing treatment (n=59) and (D) 300 cells/μL, patients randomised to ICS-containing treatment (n=53).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brightling CE, McKenna S, Hargadon B et al. . Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60:193–8. doi:10.1136/thx.2004.032516 - DOI - PMC - PubMed
    1. Ortega HG, Liu MC, Pavord ID et al. . Mepolizumab treatment in subjects with severe eosinophilic asthma. N Engl J Med 2014;371:1198–207. doi:10.1056/NEJMoa1403290 - DOI - PubMed
    1. Bafadhel M, McKenna S, Terry S et al. . Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48–55. doi:10.1164/rccm.201108-1553OC - DOI - PMC - PubMed
    1. Pascoe S, Locantore N, Dransfield MT et al. . Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435–42. doi:10.1016/S2213-2600(15)00106-X - DOI - PubMed
    1. Siddiqui SH, Guasconi A, Vestbo J et al. . Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:523–5. doi:10.1164/rccm.201502-0235LE - DOI - PMC - PubMed

Associated data

LinkOut - more resources